OrthoPediatrics today priced its initial public offering at $13 per share, meaning the 4-million-share flotation pulled in $52 million for its line of surgical systems for children.
The offering includes a 30-day underwriters over-allotment of 600,000 extra shares, which if fully exercised would push the IPO’s total raise to $59.8 million.
Warsaw, Ind.-based OrthoPediatrics produces 21 surgical systems designed to support orthopedic trauma cases and said it has plans to expand its offerings into additional categories, including foot & ankle, hand & wrist, clavicle, pelvis and sports-related injuries.
Shares trading on the NASDAQ exchange under the “KIDS” symbol were up 45.6% to $18.91 in mid-day trading today.
The proceeds are earmarked for dealing out unpaid dividends the company’s Series B preferred stock, investing in implants and instrument sets for customer consignment and for R&D, sales expansion and general corporate purposes, the company said.
Piper Jaffray and Stifel, Nicolaus are acting as joint book-runners for the offering, which is set to close Oct. 16.
The company originally registered for an initial public offering worth $75 million in June, but modified the range to between $12 and $14 per share earlier this month.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.